




D

```

cctccaccgcg ccagcccttg gcttggactc tgtcttccac ctgaagGTGT 26358948
GTCCTGGAC ATCCTGCAGC GGACAGGCCA CAAGGGGTAC GTGGCTTCC 26358898
ACAGGCCA CAAGGGGTAC GTGGCTTCC repair template
TCGAGAGCCT GGAGCTCTAC TACCTCAGT TATACCGGAA AGTCACTGGC 26358848
TCGAGAGCCT GGAGCTCTAC TACCTCAGT TATACCGGAA AGTCACTGGC
AAGGAGCCAG CACGCGTCTT CTCATGATC ATTGgtgaga ggcacgggtg 26358798
(R101C)TGC PAM sgRNA antisense
CCATGATC ATTGgtgaga ggcac
AAGGAGCCAG CACGCGTCTT CTCATGATC ATTGgtgaga ggcacgggtg
tgggtgttg ctgtgggtg actcgggtc tggcttctat gatggcgtg 26358748
Tgggtgttg ctgtgggtg actcgggtc tggcttctat gatggcgtg
gagtactaa gtgtgataac aagccttacg atgtagatca gggtagtgtg 26358698
gag
  
```



H

Clone	pS104		
	3702-2 BSA	R101C/pS104	S104
4F9.A8	1.319	1.418	0.042
4F9.B7	1.517	1.572	0.045
4F9.C5	2.180	2.130	0.049
4F9.D3	2.700	2.447	0.058
4F9.F1	2.081	2.005	0.049
4F9.H5	2.376	2.278	0.054
15F3.B2	2.224	2.185	0.050
15F3.E8	2.473	2.215	0.050
15F3.F6	2.581	2.382	0.056
15F3.G4	2.451	2.439	0.054
15F3.H2	2.605	2.254	0.075
15F3.H4	2.617	2.422	0.083








Figure S1. CARD9 linker residues R101 and S104 are required to elicit cytokine responses, Related to Figures 1 and 2.

- (A) IL-6 concentration in the supernatants from *Card9*^{-/-} BMDCs transduced with lentiviruses containing empty vector (FS), full-length CARD9 WT, CARD9 R101C, or CARD9 S104N and stimulated with HKCA (MOI 1:10), HKTR (MOI 1:10), WGP (50 µg/ml), or LPS (10ng/ml) for 24 h. (n=3 mice per condition).
- (B) Tnf concentration in the supernatants from *Card9*^{-/-} BMDMs transduced with lentiviruses containing empty vector (FS), CARD9 WT, CARD9 WT diluted 1:2, CARD9 WT diluted 1:4, CARD9 R101C, CARD9 S104N, CARD9 S104D, or CARD9 R101C/S104D and stimulated with HKCA (MOI 1:10), HKTR (MOI 1:10), or LPS (10 ng/ml) for 24 h. (n=3 mice per condition).
- (C) Expression of CARD9 in the lysates from (B) determined by western blot with the indicated antibodies. Molecular weight markers (kDa) are shown to the left.
- (D) Schematic representation of CRISPR knock-in of the *Card9* allele to obtain endogenous CARD9 R101C mutation.
- (E) Sequencing result highlighting the presence of the mutated base pair (arrows).
- (F-G) Representative western blots of (F) BMDCs and (G) splenic CD11c⁺ cells isolated from WT or *Card9* R101C mice. Molecular weight markers (kDa) are shown to the left.
- (H) Table summarizing hybridoma screening results for binding affinity of different pS104-specific antibodies. ELISA results are shown as values of absorbance at 490 nM, representing antibody reactivity towards pS104, R101C/pS104, or S104 peptides. The antibody used in the study is highlighted in yellow.
- (I) IL-6 concentration in supernatants from WT, *Card9*^{-/-}, or *Card9* R101C BMDCs treated with indicated concentrations of HKCA, HKTR, WGP, or LPS (10 ng/ml) for 24 h. (n=3 mice per condition).
- (J) Tnf concentration in WT, *Card9*^{-/-}, or *Card9* R101C BMDMs treated with HKCA (MOI 1:10), HKTR (MOI 1:10), WGP (50 µg/ml), or LPS (10 ng/ml) for 24 h.
- (K) Nuclear p65 translocation in WT, *Card9*^{-/-}, or *Card9* R101C BMDMs treated with HKCA (MOI 1:10), HKTR (MOI 1:10), or LPS (10 ng/ml) for 30 min.
- (L) IL-6 concentration in supernatant from WT, *Card9*^{-/-}, or *Card9* R101C bone marrow monocytes treated with HKCA (MOI 1:10), HKTR (MOI 1:10), WGP (50 µg/ml), or LPS (10 ng/ml) for 24 h.
- (M) Tnf concentration in supernatant from WT, *Card9*^{-/-}, or *CARD9* R101C bone marrow monocytes treated with HKCA (MOI 1:10), HKTR (MOI 1:10), WGP (50 µg/ml), or LPS (10 ng/ml) for 24 h.
- Each experiment was repeated 3 times. Data represent mean +/- SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 from paired t-tests.




Figure S2. CARD9 R101 functions as a signaling switch activated by S104 phosphorylation, Related to Figure 3.

(A) IL-6 concentration in supernatant from BMDCs expressing Cas9 transduced with guides for the corresponding genes on day 2 and selected with puromycin. On day 9, cells were stimulated with HKCA (MOI 1:10), HKTR (1:10), or WGP (50 μ g/ml) overnight.

(B) IL-6 concentration in supernatant from WT, WT pretreated with PKCdi (sotrastaurin), and *Card9*^{-/-} BMDCs treated with HKCA (MOI 1:10), HKTR (MOI 1:10), or WGP (50 μ g/ml) overnight.

(C) Tnf concentration in supernatant from WT, WT pretreated with PKCdi (sotrastaurin), and *Card9*^{-/-} BMDCs treated with HKCA (MOI 1:10), or HKTR (MOI 1:10), or WGP (50 μ g/ml) overnight.

(D) Representative western blot showing expression of CARD9 2-152 variants and MBP-BCL10 in BL21 DE3 cells at indicated timepoints from soluble (S) and insoluble (In) fractions. Molecular weight markers (kDa) are shown to the left.

(E) Normalized fluorescence polarization representing filament formation between different CARD9 2-152 variants and MBP-tagged BCL10 (average of quadruplicates).

(F) IL-6 concentration in supernatants from *Card9*^{-/-} BMDCs transduced with lentiviruses containing empty vector (FS), CARD9 WT, CARD9 WT diluted 1:2, CARD9 WT diluted 1:4, CARD9 S104D, or CARD9 R101C/S104D and stimulated with HKCA (MOI 1:10), HKTR (MOI 1:10), WGP (50 μ g/ml), or LPS (10 ng/ml) for 24 h. (n=3 mice per condition).

Each experiment was repeated 3 times. Data represent mean \pm SEM. * p <0.05, ** p <0.01, *** p <0.001, **** p <0.0001 from paired t-tests.









Figure S3. Card9 R101C mice are predisposed to systemic fungal infection, Related to Figure 4.

- (A) Flow cytometry analysis of T cell composition in the spleen from 12-week-old mice (n=4 for each genotype).
- (B) Flow cytometry analysis of B cell composition in the spleen from 12-week-old mice (n=4 for each genotype). Total B cells (B220⁺), follicular B cells (B220⁺, CD23^{hi}, CD21/35^{int}), marginal zone B cells (B220⁺, CD21/35^{hi}, CD23^{low}).
- (C) Flow cytometry analysis of myeloid cell composition in the spleen from 12-week-old mice (n=4 for each genotype).
- (D) Flow cytometry analysis of naïve T cell composition in the thymus from 12-week-old mice (n=4 for each genotype). DN1 (CD44⁺, CD25⁻), DN2 (CD44⁺, CD25⁺), DN3 (CD44⁻, CD25⁺), DN4 (CD44⁻, CD25⁻).
- (E) Flow cytometry analysis of early T cell progenitor (CD44⁺, CD25⁻, cKit⁺) composition in the thymus from 12-week-old mice (n=4 for each genotype).
- (F) Flow cytometry analysis of T cell composition in the thymus from 12-week-old mice (n=4 for each genotype). DP (CD4⁺, CD8⁺), DN (CD4⁻, CD8⁻), SP4 (CD4⁺, CD8⁻), SP8 (CD4⁻, CD8⁺).
- (G) Flow cytometry analysis of bone marrow Hardy fractions D-F from 12-week-old mice (n=4 for each genotype). Fractions D (B220⁺, CD43⁻), E (B220⁺, CD43⁻, IgM⁺), F (B220⁺, CD43⁻, IgM⁺, IgD⁺).
- (H) Flow cytometry analysis of bone marrow Hardy fractions A-C from 12-week-old mice (n=4 for each genotype). Fractions A (B220⁺, CD43⁺, BP-1⁻, CD24⁻), B (B220⁺, CD43⁻, CD24⁺, BP-1⁻), C (CD22⁺, CD43⁺, CD24⁺, BP-1⁺).
- (I) Gating strategy applied to analyze kidney samples.
- (J-L) Flow cytometry analysis of (J) macrophages, (K) dendritic cells (DCs), and (L) eosinophils in kidneys from mice injected intravenously with live *C. albicans* analyzed on day 2 post-injection (n=4 for each genotype).
- (M) Gating strategy applied to analyze brain samples.
- (N-P) Flow cytometry analysis of (N) macrophages, (O) DCs, and (P) eosinophils in the brains from mice injected intravenously with live *C. albicans* analyzed on day 2 post-injection (n=4 for each genotype).
- (Q) Gating strategy applied to analyze spleen samples.
- (R-W) Flow cytometry analysis of (R) macrophages, (S) total DCs, (T) CD8a⁺ or CD11b⁺ DCs, (U) neutrophils, (V) inflammatory monocytes, and (W) eosinophils in the spleens from mice injected intravenously with live *C. albicans* analyzed on day 2 post-injection (n=4 for each genotype).
- Experiments were repeated at least 2 times. Data represent mean +/- SEM. *p<0.05 from paired t-tests.




Figure S4. Card9 R101C mutation impairs spore clearance in a mouse model of dermatophytosis, Related to Figure 5.

(A) Gating strategy applied to skin samples.

(B) CFUs from foot pads of mice injected with live *T. rubrum* analyzed on day 9 post-injection (n=4 for each genotype).

(C) Flow cytometry analysis of neutrophils in the foot pads from mice in (B).

(D) Cxcl1 concentration in the foot pads from mice in (B) measured by ELISA.

Each experiment was repeated at least 2 times. Data represent mean +/- SEM. *p<0.05, **p<0.01 from paired t-tests.




Figure S5. Top differentially expressed genes for immune, stromal, and keratinocyte clusters identified in scRNA-seq analysis, and additional markers expressed in keratinocytes, Related to Figure 6.

(A) Top 10 DEGs for each immune cluster. For each cluster, DEGs were defined as genes significantly differentially expressed (FDR $P < 0.05$) for the indicated cluster versus all other immune clusters.

(B) Log-normalized expression of representative markers differentiating the Mono1 and Mono2 clusters.

(C) Log-normalized expression of key markers defining Langerhans cells.

(D) Top 10 DEGs for each stromal cluster. For each cluster, DEGs were defined as genes significantly differentially expressed (FDR $P < 0.05$) for the indicated cluster versus all other stromal clusters.

(E) Top 10 DEGs for each keratinocyte cluster. For each cluster, DEGs were defined as genes significantly differentially expressed (FDR $P < 0.05$) for the indicated cluster versus all other keratinocyte clusters.

(F) GSEA showing that the keratinocyte clusters identified in the present study are enriched in previously identified keratinocyte states [S1]. Specifically, for each of our clusters, we used the full list of DEGs for the cluster as defined in (E) as input to a GSEA pre-ranked analysis using gene signatures for previously defined keratinocyte clusters [S1], indicated by the text labels beneath the heatmap. A high normalized enrichment score (NES) indicates positive enrichment of our clusters in the previously identified clusters [S1]; a low NES indicates negative enrichment of our clusters in the previously identified clusters [S1].

(G) Selected top DEGs for each of the four keratinocyte clusters. Dot size indicates mean expression across all cells in each cluster across timepoints and *Card9* genotypes.

(H) Relative expression of *Card9* across all immune clusters.

See also Tables S1-S4.




Figure S6. Top differentially expressed genes between WT and R101C cells for major immune clusters, Related to Figure 6.

(A-E) Heatmaps show top upregulated and downregulated genes for each cluster between WT and R101C cells at D2. Row annotations show differential expression of the corresponding gene for the R101C D2 vs D9 comparison, WT D2 vs D9 comparison, and D9 WT vs R101C comparison.

(F-H) Expression of Ly6C genes among CD45⁺ cells in infected WT or R101C skin.

(I-N) Expression of cytokines and chemokines among CD45⁺ cells in infected WT or R101C skin.

See also Tables S1-S4.

were calculated using a two-sided Wilcoxon test. n.s., not significant.

(E-G) Heatmaps showing (E) keratin family genes, (F) collagen family genes, and (G) transcription factors differentially expressed between WT and R101C keratinocytes.

(H) Wound healing genes from gene ontology differentially expressed in each keratinocyte cluster in WT and R101C cells at D2 or D9. Dotted lines indicate fold-change cutoff. Selected DEGs highlighted in blue.

(I) Inflammatory response genes from gene ontology differentially expressed in each keratinocyte cluster in WT and R101C cells at D2 or D9. Dotted lines indicate fold-change cutoff. Selected DEGs highlighted in blue.

See also Tables S3-S6.

Supplemental References

[S1] Joost, S., Zeisel, A., Jacob, T., Sun, X., La Manno, G., Lönnerberg, P., Linnarsson, S., and Kasper, M. (2016). Single-Cell Transcriptomics Reveals that Differentiation and Spatial Signatures Shape Epidermal and Hair Follicle Heterogeneity. *Cell Syst* 3, 221–237.e9.